Literature DB >> 2300411

Long term serologic follow-up after pertussis immunization.

M Blennow1, M Granström.   

Abstract

Neutralizing antibodies to pertussis toxin (antitoxin) were determined in 201 blood samples from 4-year-old children. They had received primary immunization at 6 to 8 months of age with an acellular (n = 149) or a whole cell (n = 52) pertussis vaccine and 195 of them had received a booster dose of the acellular vaccine 9 to 16 months later. Data on exposure to pertussis and occurrence of pertussis were also collected. There was a rapid decrease of antitoxin between immediate postbooster titers and those measured 24 months later. This decrease per month was significantly greater than that after the primary immunization series (P less than 0.001). Neither the number nor the spacing of acellular vaccine doses given for primary series influenced the titers found 24 months after the booster. An antitoxin response was still measurable in 86% of the 196 four-year-old children. None of 19 exposed children developed whooping cough, which suggested that the antibody concentrations during the follow-up period were sufficient for protection. The results indicate a need for long term follow-up studies in the evaluation of new vaccines and immunization schedules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300411     DOI: 10.1097/00006454-199001000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.

Authors:  E Grimprel; P Bégué; I Anjak; E Njamkepo; P François; N Guiso
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

2.  Isolation of Bordetella bronchiseptica from a patient with AIDS.

Authors:  R Mesnard; N Guiso; C Michelet; J M Sire; P Pouëdras; P Y Donnio; J L Avril
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

3.  Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age.

Authors:  M Granström; Y Tindberg; M Blennow
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 4.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups.

Authors:  Aapo Knuutila; Pauline Versteegen; Alex-Mikael Barkoff; Pieter van Gageldonk; Jussi Mertsola; Guy Berbers; Qiushui He
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.